ClinicalTrials.gg
CompletedNCT04102150Updated Feb 10, 2025

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

A Phase 2 interventional study of Valemetostat Tosylate in Adult T-cell Leukemia/Lymphoma, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 24 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).

02

Conditions studied

  • Adult T-cell Leukemia/Lymphoma
03

In context

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

This study's enrollment of 25 is below the median of 30 across 322 interventional studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with adult T-cell leukemia/lymphoma (ATL) who have history of treatment with mogamulizumab or are mogamulizumab intolerant, after treatment with at least 1 medication regimen
  • Aged ≥20 years or older at the time of signing the
  • (ECOG) performance status (PS) of 0-2
  • At least 1 evaluable lesion
  • Participants who have defined laboratory criteria
  • ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • A presence of central nervous system involvement at the time of screening tests
  • Have poorly controlled complication (eg. chronic congestive heart failure, unstable angina
  • ≥ Grade 3 neuropathy
  • corrected using Fridericia's method (QTcF) >470 ms
  • Has an uncontrolled infection
  • Participants who use over 10 mg/day
  • Receipt of hematopoietic stem cell transplantation
  • History of, or concurrent, malignant tumors
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    DS-3201b

    Drug: Valemetostat Tosylate

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) assessed by central evaluation organization

    The percentage of participants who were assessed for best overall response, who achieved complete remission (CR), complete remission, unconfirmed (CRu) or partial remission (PR) by central evaluation organization.

    Time frame: Through the end of the study (within approximately 5 years)

Secondary outcomes

  1. Overall response rate (ORR) assessed by investigator

    The percentage of participants who were assessed for best overall response, who achieved CR, CRu, or PR by investigator.

    Time frame: Through the end of the study (within approximately 5 years)

  2. Best response per tumor lesions

    Best response in target lesions (nodal or extranodal lesions), peripheral blood lesions, and skin lesions.

    Time frame: Through the end of the study (within approximately 5 years)

  3. Complete remission rate (CR rate)

    The percentage of participants who were assessed for best overall response, who achieved CR or CRu.

    Time frame: Through the end of the study (within approximately 5 years)

  4. Tumor control rate (TCR)

    The percentage of participants who were assessed for best overall response, who achieved CR, CRu, PR or stable disease (SD).

    Time frame: Through the end of the study (within approximately 5 years)

  5. Time to response (TTR)

    Period from the first day of DS-3201b dose to the first day of CR, CRu, or PR

    Time frame: Through the end of the study (within approximately 5 years)

  6. Duration of response (DOR)

    Period from first CR, CRu, or PR to residual disease/progressive disease (RD/PD) or death.

    Time frame: Through the end of the study (within approximately 5 years)

  7. Progression-free survival (PFS)

    Period from the first day of DS-3201b dose to the day of RD/PD or death.

    Time frame: Through the end of the study (within approximately 5 years)

  8. Overall survival (OS)

    Period from the first day of DS-3201b dose to death.

    Time frame: Through the end of the study (within approximately 5 years)

07

Study locations

24 sites
  • Nagoya City University Hospital
    Nagoya-shi, Aichi, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba, Japan
  • Ehime University Hospital
    Tōon-shi, Ehime, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka-shi, Fukuoka, Japan
  • Hokkaido University Hospital
    Sapporo-shi, Hokkaido, Japan
  • Imamura General Hospital
    Kagoshima-shi, Kagoshima, Japan
  • Kochi Medical School Hospital
    Nankoku-shi, Kochi, Japan
  • Kumamoto University Hospital
    Kumamoto-shi, Kumamoto, Japan
  • National University Corporation Tohoku University Tohoku University Hospital
    Sendai-shi, Miyagi, Japan
  • University of Miyazaki Hospital
    Miyazaki-shi, Miyazaki, Japan
  • Local Incorporated Administrative Agency Sasebo City General Hospital
    Sasebo-shi, Nagasaki, Japan
  • Okayama University Hospital
    Okayama-shi, Okayama, Japan
  • University of the Ryukyus Hospital
    Nakagami-gun, Okinawa, Japan
  • Osaka International Cancer Institute
    Osaka-shi, Osaka, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka, Japan
  • Osaka University Hospital
    Suita-shi, Osaka, Japan
  • Saga University Hospital
    Saga-shi, Saga, Japan
  • Saitama Medical University International Medical Center
    Hidaka-shi, Saitama, Japan
  • Hamamatsu University Hospital
    Hamamatsu-shi, Shizuoka, Japan
  • National Cancer Center Hospital
    Chuo Ku, Tokyo, Japan
  • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo
    Minato-Ku, Tokyo, Japan
  • Kagoshima University Hospital
    Kagoshima-city, Japan
  • Nagasaki University Hospital
    Nagasaki-shi, Japan
08

References and documents

Publications

  • Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023 Mar 9;141(10):1159-1168. doi: 10.1182/blood.2022016862. PubMed 36150143 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Apr 2021, 17 months.

Of 44 phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 97. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Nov 21, 2019
Primary completionActual
Apr 24, 2021
CompletionActual
Oct 27, 2024
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04102150
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Nov 21, 2019
Primary completion
Apr 24, 2021
Completion
Oct 27, 2024
Last update
Feb 10, 2025

Study contacts

Clinical Study Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valemetostat tosylate

Start the discussion